Literature DB >> 12767520

The insulin-like growth factor system and cancer.

Derek LeRoith1, Charles T Roberts.   

Abstract

The insulin-like growth factor (IGF) family of ligands, binding proteins and receptors is an important growth factor system involved in both the development of the organism and the maintenance of normal function of many cells of the body. The system also has powerful anti-apoptotic effects. More recently, evidence has accrued to demonstrate that the IGFs play an important role in cancer. Individuals with serum IGF-II levels in the upper quartile of the normal range (and IGF binding protein-3 levels in the lower quartiles) have a relative risk for developing breast, prostate, colon and lung cancer. IGF-II is commonly expressed by tumor cells and may act as an autocrine growth factor; occasionally even reaching target tissues and causing tumor-induced hypoglycemia. The IGF-I receptor is commonly (though not always) overexpressed in many cancers, and many recent studies have identified new signaling pathways emanating from the IGF-I receptor that affect cancer cell proliferation, adhesion, migration and cell death; functions that are critical for cancer cell survival and metastases. In this review, many aspects of the IGF system and its relationship to cancer will be discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767520     DOI: 10.1016/s0304-3835(03)00159-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  336 in total

1.  Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.

Authors:  Gang Xi; Xinchun Shen; Yashwanth Radhakrishnan; Laura Maile; David Clemmons
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

Review 2.  What's new in the IGF-binding proteins?

Authors:  Steven A Rosenzweig
Journal:  Growth Horm IGF Res       Date:  2004-10       Impact factor: 2.372

3.  Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Authors:  Scott W Blume; Nateka L Jackson; Andra R Frost; William E Grizzle; Oleg D Shcherbakov; Hyoungsoo Choi; Zheng Meng
Journal:  Exp Mol Pathol       Date:  2010-03-15       Impact factor: 3.362

Review 4.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

5.  A lncRNA promotes myoblast proliferation by up-regulating GH1.

Authors:  Yingwei Yue; Congfei Jin; Mingming Chen; Linlin Zhang; Xinfeng Liu; Wenzhi Ma; Hong Guo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-07-19       Impact factor: 2.416

6.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

7.  Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Authors:  Sara A Flanigan; Todd M Pitts; Timothy P Newton; Gillian N Kulikowski; Aik Choon Tan; Martine C McManus; Anna Spreafico; Maria I Kachaeva; Heather M Selby; John J Tentler; S Gail Eckhardt; Stephen Leong
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

8.  Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma.

Authors:  Minoru Tomizawa; Hiromitsu Saisho
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

9.  Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure.

Authors:  Jun Shen; Jie Liu; Yaxiong Xie; Bhalchandra A Diwan; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2006-10-31       Impact factor: 4.849

10.  Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Authors:  Luca Szalontay; Andrew V Schally; Petra Popovics; Irving Vidaurre; Awtar Krishan; Marta Zarandi; Ren-Zhi Cai; Anna Klukovits; Norman L Block; Ferenc G Rick
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.